Praluent (Alirocumab) for Familial Hypercholesterolemia: What Women Need to Know

What Is the FDA-Approved Indication for Praluent, and Where Does FH Fit?

Alirocumab received FDA approval in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who need additional LDL-lowering beyond maximally tolerated statin therapy. That approval rested on the ODYSSEY clinical program, a suite of trials enrolling more than 23,000 patients across multiple substudies.

So the short answer to "can you use Praluent for FH" is: yes, for HeFH in adults, it is on-label. The nuance matters because FH is not one condition. It spans:

• Heterozygous FH (HeFH): one defective LDL receptor allele; LDL-C typically 190-400 mg/dL
• Homozygous FH (HoFH): two defective alleles; LDL-C often 400-1000 mg/dL; far more severe

For HoFH in adults and for any FH in patients under 18, alirocumab use remains off-label. This article addresses both the approved and off-label territory with attention to what the evidence actually shows.

Why FH Matters More for Women Than Cardiology Textbooks Suggest

FH affects an estimated 1 in 250 people in the general population, making it the most common inherited lipid disorder. Women with FH are diagnosed later than men on average, receive aggressive therapy less often, and reach cardiovascular events later in life but at a substantially younger age than women without FH. The EAS Consensus Panel 2013 explicitly noted underdiagnosis in women as a systemic failure.

Estrogen during the reproductive years partially suppresses LDL-C and raises HDL-C, which can mask the severity of FH on a standard lipid panel. This is not protective in FH the way it appears, because the structural receptor defect continues driving atherosclerosis regardless of estrogen status.

How Alirocumab Works and Why PCSK9 Inhibition Is Logical for FH

The PCSK9 Pathway

PCSK9 is a serine protease that degrades LDL receptors in the liver. When PCSK9 binds a receptor, it prevents recycling to the hepatocyte surface. Alirocumab is a fully human monoclonal antibody that binds and neutralizes circulating PCSK9, preserving more LDL receptors, so more LDL-C is cleared from blood. In patients with HeFH, one functioning LDL receptor allele remains, meaning PCSK9 inhibition can still extract meaningful benefit. In HoFH with null-null mutations, the receptor-dependent mechanism is blunted, which limits efficacy but does not eliminate it entirely.

Sex-Specific Pharmacokinetics

Population pharmacokinetic analyses from the ODYSSEY program found that body weight and sex both influence alirocumab exposure. Women, who generally have lower body weight and different adipose distribution, tend to reach higher alirocumab peak concentrations per milligram dose than men. The FDA label pharmacokinetics section states that no dose adjustment is required based on sex, though the exposure difference exists. The clinical consequence of this pharmacokinetic difference in women has not been studied as a primary endpoint in any published alirocumab trial, which is a genuine evidence gap worth naming.

The Evidence Base: ODYSSEY FH I and FH II

The primary evidence for alirocumab in HeFH comes from ODYSSEY FH I and FH II, published in 2015 in the European Heart Journal. Both were randomized, double-blind, placebo-controlled trials.

ODYSSEY FH I (n=486)

Patients on maximally tolerated statins with or without other lipid-lowering therapy received alirocumab 75 mg every 2 weeks or placebo for 78 weeks. The alirocumab group achieved a mean LDL-C reduction of 57.9% at week 24, compared with a 0.8% increase in the placebo group. Dose was uptitrated to 150 mg every 2 weeks at week 12 if LDL-C remained above 70 mg/dL.

ODYSSEY FH II (n=249)

A parallel trial design with a similar population showed a 51.4% LDL-C reduction at week 24 in the alirocumab arm versus a 2.8% reduction with placebo. Women represented approximately 40% of participants across both substudies, which is better representation than earlier lipid trials but still leaves some uncertainty about sex-stratified effect sizes.

ODYSSEY OUTCOMES: Cardiovascular Event Reduction

The ODYSSEY OUTCOMES trial published in 2018 in the New England Journal of Medicine enrolled 18,924 patients with recent acute coronary syndrome and randomized them to alirocumab 75-150 mg every 2 weeks or placebo on top of high-intensity statin therapy. The primary composite endpoint (coronary heart disease death, nonfatal MI, ischemic stroke, unstable angina hospitalization) occurred in 9.5% of the alirocumab group versus 11.1% of the placebo group, a hazard ratio of 0.85 (95% CI 0.78-0.92, p<0.001). Women comprised 24.9% of ODYSSEY OUTCOMES. Subgroup analyses did not show a statistically significant interaction by sex, suggesting directionally consistent benefit, but the sex-specific confidence intervals are wide.

Off-Label Territory: Homozygous FH in Adults

Where the Evidence Is Thinner

Alirocumab is not FDA-approved for HoFH. Evolocumab (Repatha) holds that approval. The reason is mechanistic: PCSK9 inhibition depends on residual LDL receptor function. In true null-null HoFH, receptors are absent, so PCSK9 inhibition produces little or no LDL-C reduction. In receptor-defective HoFH (the more common variant), some response occurs.

A 2020 case series and expanded access data showed alirocumab producing LDL-C reductions of 10-25% in receptor-defective HoFH patients, far below the 50-60% seen in HeFH. This is GRADE C evidence at best: observational, small sample, no randomized controlled trial in HoFH with alirocumab as the primary intervention.

Guideline Position

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies supports PCSK9 inhibitor use in HoFH when LDL-C remains uncontrolled despite statins, ezetimibe, and lomitapide, but it names evolocumab as the preferred agent. Alirocumab may be used when evolocumab is unavailable, contraindicated, or not tolerated, making it an off-label but guideline-adjacent choice in that circumstance. Clinicians should document the rationale clearly in the chart.

The WomanRx Off-Label Evidence Tier for Alirocumab in FH:

| FH Type | Regulatory Status | Evidence Grade | Guideline Support | |---|---|---|---| | HeFH (adult) | FDA-approved | A (multiple RCTs) | ACC, AHA, EAS | | HeFH (under 18) | Off-label | B (limited pediatric data) | ACC pathway, case-by-case | | HoFH (receptor-defective) | Off-label | C (observational) | Evolocumab preferred; alirocumab secondary | | HoFH (null-null) | Off-label | D (mechanistically limited) | Not supported as first-line |

Dosing and Administration for Women

Alirocumab comes in two doses: 75 mg per mL and 150 mg per mL prefilled autoinjectors or syringes. The standard approach is:

1. Start at 75 mg subcutaneously every 2 weeks
2. Measure LDL-C at 4-8 weeks
3. Uptitrate to 150 mg every 2 weeks if LDL-C target is not met
4. Alternatively, 300 mg every 4 weeks is an approved dosing schedule for patients preferring monthly injection

Injection sites are the abdomen, thigh, or upper arm. Rotate sites to reduce local reactions, which occurred in 7.2% of alirocumab patients in pooled trial data versus 5.1% with placebo.

No dose adjustment is required for mild-to-moderate renal impairment or hepatic impairment. Data in severe impairment are limited.

Pregnancy and Lactation: A Required Conversation for Every Woman With FH

Alirocumab is contraindicated in pregnancy. This must be stated plainly and discussed early in any consultation with a woman of reproductive age.

Why the Concern Exists

Preclinical studies in monkeys showed no direct fetal harm at doses up to 15 times the maximum recommended human dose, but PCSK9 is expressed in the placenta and fetal liver. Human data on alirocumab in pregnancy are extremely limited, consisting of sporadic case reports and registry entries, not controlled trials. The FDA label assigned a precautionary stance rather than a formal pregnancy category (the old A-D-X system was retired in 2015), but states that alirocumab should be discontinued before a planned pregnancy.

Statins, the backbone of FH therapy, are also contraindicated in pregnancy. This creates a genuine management gap for pregnant women with HeFH: their LDL-C rises substantially during pregnancy (sometimes 30-50% above pre-pregnancy levels due to normal physiological changes), and the safest pharmacological options are bile acid sequestrants such as cholestyramine or colesevelam.

Contraception Requirement

Any woman of reproductive potential taking alirocumab should use reliable contraception. Because alirocumab is a monoclonal antibody with a half-life of approximately 17-20 days, clinicians typically advise stopping the drug at least one to two months before a planned conception attempt, though no specific washout period is defined in the label.

Lactation

No data exist on alirocumab transfer into human breast milk. IgG antibodies do transfer into breast milk, but oral bioavailability of large proteins in the breastfed infant is expected to be negligible. The FDA label states the drug is not recommended during breastfeeding due to the absence of human data. Women who need aggressive LDL-lowering while breastfeeding should have a documented risk-benefit discussion with their clinician.

Postpartum Consideration

Postpartum LDL-C can spike above pre-pregnancy levels as estrogen withdraws and the lipid physiology resets. For a woman with HeFH who just delivered, this is often the moment when untreated or under-treated FH becomes most apparent. Restarting alirocumab after weaning, or transitioning off bile acid sequestrants, should be planned before delivery, not after an urgent lipid check reveals dangerous numbers.

Alirocumab Across the Female Life Span

Reproductive Years (Ages 18-40)

Women in reproductive years who have confirmed HeFH and LDL-C persistently above 190 mg/dL despite statin therapy are candidates for alirocumab. The overlap with potential pregnancy means the contraception conversation is non-negotiable at every visit. The 2018 ACC/AHA cholesterol guideline recommends PCSK9 inhibitor consideration in adults with HeFH and LDL-C above 100 mg/dL on maximally tolerated statin therapy, or above 70 mg/dL in the presence of established ASCVD.

Trying to Conceive

Alirocumab must be stopped. Bile acid sequestrants are the preferred bridge. Women planning pregnancy should have a lipid management plan documented at least three months before they begin trying, not at the first prenatal visit.

Perimenopause (Typically Ages 45-55)

This is the life stage where FH risk accelerates most dramatically in women. Estrogen decline removes a partial buffering effect on LDL-C, and some women who appeared mildly affected by FH during reproductive years see their LDL-C surge by 20-40 mg/dL during the menopause transition. Women who were managing adequately on statin monotherapy may suddenly need an add-on agent, and alirocumab becomes far more clinically relevant at this stage.

Menopausal hormone therapy (MHT) lowers LDL-C modestly (oral estrogen) or has a neutral-to-modest effect (transdermal estrogen). MHT does not replace the LDL-lowering needed for FH management but can complement it. The two therapies can be used together without known pharmacokinetic interactions.

Postmenopause

After menopause, the cardiovascular risk in women with HeFH approaches and may exceed that in age-matched men with HeFH, erasing the female advantage seen earlier in life. Aggressive LDL-C management with alirocumab is appropriate and well-supported in this group by the ODYSSEY OUTCOMES data, though the trial enrolled relatively few women over 65.

Who This Is Right For (and Who Should Pause)

Strong Candidates

• Women with confirmed HeFH (genetic diagnosis or Dutch Lipid Clinic Network score above 8) and LDL-C above 100 mg/dL on maximally tolerated statin plus ezetimibe
• Women with HeFH and established ASCVD (prior MI, stroke, coronary revascularization) and LDL-C above 70 mg/dL on maximum tolerated therapy
• Postmenopausal women with markedly elevated LDL-C newly recognized as FH
• Women with statin intolerance who have confirmed FH

Situations Requiring Caution or Deferral

• Active pregnancy or planning pregnancy within two months
• Breastfeeding with no acceptable alternative
• Women with HoFH and null-null mutations (mechanistically limited benefit)
• Women with very low baseline LDL-C who are already at target

Conditions That Commonly Coexist With FH in Women

Women with FH often carry additional risk burdens worth factoring into the shared decision:

• PCOS: independently raises LDL-C, triglycerides, and small dense LDL; synergizes with FH risk
• Hypothyroidism: raises LDL-C through reduced LDL receptor expression; must be treated before adding a third lipid agent
• Obesity: worsens the atherogenic lipid profile in FH and may reduce statin adherence due to myalgia concerns

Monitoring and Safety Signals Relevant to Women

Alirocumab is generally well tolerated. The most clinically meaningful signals are:

• Injection site reactions: mild erythema and pruritus in about 7% of users
• Neurocognitive symptoms: reported sporadically; FDA added a label warning in 2017 but the causality remains unclear; the EBBINGHAUS substudy of FOURIER (the evolocumab counterpart trial) found no cognitive impairment signal on formal testing
• Very low LDL-C: ODYSSEY OUTCOMES included patients reaching LDL-C below 15 mg/dL without safety signal over approximately three years, but long-term data (over a decade) are absent

No sex-specific safety signals unique to women have been established in the published trial data, which itself reflects the evidence gap. Women were underrepresented in most ODYSSEY substudies, and no subgroup analysis stratified by menopausal status has been published.

What Genetic Testing Adds

Genetic confirmation of FH strengthens the case for alirocumab both clinically and from an insurance coverage standpoint. Pathogenic variants in LDLR (most common), APOB, or PCSK9 confirm the diagnosis. A negative genetic panel does not rule out FH; approximately 20-40% of clinically diagnosed FH patients have no identified variant. Most U.S. Commercial insurers require prior authorization for PCSK9 inhibitors, and documenting confirmed or probable FH by a validated clinical score is usually required.

The Insurance and Access Gap

Prior authorization denial rates for PCSK9 inhibitors have historically ranged from 50-80% on first submission. Women with FH who are denied should ensure their chart documents LDL-C above threshold, documented statin trial, ezetimibe trial, and FH diagnosis basis. Sanofi/Regeneron maintains a patient assistance program for eligible uninsured or underinsured patients.